MedTrace Logo

Single Ascending Dose Study of RBP-7000

NCT02768649 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-05-11

No results posted yet for this study

Summary

The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia

Conditions

Interventions

DRUG

RBP-7000

Sequential dosing of each cohort

DRUG

risperidone

All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.

Sponsors & Collaborators

  • Indivior Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02768649 on ClinicalTrials.gov